Clinical Trial Update: Korea Post Marketing Surveillance (PMS) Study of Vizimpro

View source ↗

Summary

Pfizer reports the completion of the Korea post-marketing surveillance study of Vizimpro (dacomitinib) for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• VIZIMPRO (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Lung Neoplasms | Status: COMPLETED